دورية أكاديمية
أعرض في EDS

Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison.

التفاصيل البيبلوغرافية
العنوان: Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison.
المؤلفون: MacDonald SM; Massachusetts General Hospital, Boston, Massachusetts, USA., Ahmad S, Kachris S, Vogds BJ, DeRouen M, Gittleman AE, DeWyngaert K, Vlachaki MT
المصدر: Journal of applied clinical medical physics [J Appl Clin Med Phys] 2007 Apr 19; Vol. 8 (2), pp. 47-60. Date of Electronic Publication: 2007 Apr 19.
نوع المنشور: Comparative Study; Evaluation Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley on behalf of American Association of Physicists in Medicine Country of Publication: United States NLM ID: 101089176 Publication Model: Electronic Cited Medium: Internet ISSN: 1526-9914 (Electronic) Linking ISSN: 15269914 NLM ISO Abbreviation: J Appl Clin Med Phys Subsets: MEDLINE
أسماء مطبوعة: Publication: 2017- : Malden, MA : Wiley on behalf of American Association of Physicists in Medicine
Original Publication: Reston, VA : American College of Medical Physics, c2000-
مواضيع طبية MeSH: Brain Neoplasms/*radiotherapy , Glioma/*radiotherapy , Radiometry/*methods , Radiotherapy Planning, Computer-Assisted/*methods , Radiotherapy, Conformal/*methods, Dose-Response Relationship, Radiation ; Humans ; Radiotherapy Dosage
مستخلص: The present study compared the dosimetry of intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) techniques in patients treated for high-grade glioma. A total of 20 patients underwent computed tomography treatment planning in conjunction with magnetic resonance imaging fusion. Prescription dose and normal-tissue constraints were identical for the 3D-CRT and IMRT plans. The prescribed dose was 59.4 Gy delivered at 1.8 Gy per fraction using 4-10 MV photons. Normal-tissue dose constraints were 50-54 Gy for the optic chiasm and nerves, and 55-60 Gy for the brainstem. The IMRT plan yielded superior target coverage as compared with the 3D-CRT plan. Specifically, minimum and mean planning target volume cone down doses were 54.52 Gy and 61.74 Gy for IMRT and 50.56 Gy and 60.06 Gy for 3D-CRT (p < or = 0.01). The IMRT plan reduced the percent volume of brainstem receiving a dose greater than 45 Gy by 31% (p = 0.004) and the percent volume of brain receiving a dose greater than 18 Gy, 24 Gy, and 45 Gy by 10% (p = 0.059), 14% (p = 0.015), and 40% (p < or = 0.0001) respectively. With IMRT, the percent volume of optic chiasm receiving more than 45 Gy was also reduced by 30.40% (p = 0.047). As compared with 3D-CRT, IMRT significantly increased the tumor control probability (p < or = 0.005) and lowered the normal-tissue complication probability for brain and brainstem (p < 0.033). Intensity-modulated radiation therapy improved target coverage and reduced radiation dose to the brain, brainstem, and optic chiasm. With the availability of new cancer imaging tools and more effective systemic agents, IMRT may be used to intensify tumor doses while minimizing toxicity, therefore potentially improving outcomes in patients with high-grade glioma.
References: J Clin Oncol. 2002 Mar 15;20(6):1635-42. (PMID: 11896114)
J Clin Oncol. 1992 Sep;10(9):1379-85. (PMID: 1325539)
Phys Med Biol. 1993 Jun;38(6):653-66. (PMID: 8346278)
N Engl J Med. 1980 Dec 4;303(23):1323-9. (PMID: 7001230)
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):137-46. (PMID: 2032884)
Radiology. 2006 Mar;238(3):958-69. (PMID: 16424238)
Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1175-83. (PMID: 15964709)
Br J Radiol. 1961 Apr;34:246-51. (PMID: 13726846)
Can J Neurol Sci. 1998 Aug;25(3):197-201. (PMID: 9706720)
Radiother Oncol. 1993 Nov;29(2):140-7. (PMID: 8310139)
Eur J Cancer. 2006 Mar;42(5):582-8. (PMID: 16427778)
Oncogene. 2004 Dec 16;23(58):9392-400. (PMID: 15558011)
Radiat Res. 1990 Dec;124(3):273-82. (PMID: 2263727)
Med Dosim. 2003 Winter;28(4):261-5. (PMID: 14684191)
Cancer Invest. 2002;20(4):437-51. (PMID: 12094538)
Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1623-30. (PMID: 2722599)
Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1005-11. (PMID: 9719109)
Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):391-401. (PMID: 12957250)
J Neurooncol. 1994;20(2):111-20. (PMID: 7807189)
Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):743-50. (PMID: 9336158)
Neurology. 2006 Jun 27;66(12):1899-906. (PMID: 16801657)
Radiother Oncol. 2003 Nov;69(2):169-76. (PMID: 14643954)
J Formos Med Assoc. 1999 Nov;98(11):740-8. (PMID: 10705690)
Neurology. 1980 Sep;30(9):907-11. (PMID: 6252514)
J Neurosurg. 1978 Sep;49(3):333-43. (PMID: 355604)
Cancer Metastasis Rev. 1985;4(2):107-24. (PMID: 2990670)
Gen Physiol Biophys. 2005 Sep;24(3):327-35. (PMID: 16308427)
Radiologe. 2003 May;43(5):388-95. (PMID: 12764588)
Ann Neurol. 1999 Aug;46(2):183-8. (PMID: 10443883)
Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):892-7. (PMID: 16458777)
J Nucl Med. 1992 Dec;33(12 ):2133-7. (PMID: 1334136)
Radiat Res Suppl. 1985;8:S13-9. (PMID: 3867079)
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22. (PMID: 2032882)
Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):963-8. (PMID: 11704318)
Med Dosim. 2005 Summer;30(2):69-75. (PMID: 15922172)
Radiat Oncol Investig. 1998;6(4):175-81. (PMID: 9727877)
Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):71-7. (PMID: 11163499)
J Neurosurg. 1999 Aug;91(2):251-60. (PMID: 10433313)
Med Phys. 1997 Jan;24(1):103-10. (PMID: 9029544)
AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98. (PMID: 14625221)
Neurology. 2002 Jul 9;59(1):121-3. (PMID: 12105319)
Lancet. 2002 Mar 23;359(9311):1011-8. (PMID: 11937180)
Cancer. 1993 Apr 15;71(8):2585-97. (PMID: 8453582)
AJNR Am J Neuroradiol. 2005 Oct;26(9):2170-7. (PMID: 16219818)
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):123-35. (PMID: 2032883)
Br J Radiol. 2006 Nov;79(947):905-11. (PMID: 16885177)
N Engl J Med. 2005 Mar 10;352(10 ):997-1003. (PMID: 15758010)
Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22. (PMID: 12007936)
Med Phys. 2006 Jan;33(1):32-40. (PMID: 16485406)
Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):51-5. (PMID: 10656372)
Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1045-53. (PMID: 8985026)
Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):61-70. (PMID: 12909216)
Curr Neurol Neurosci Rep. 2005 May;5(3):198-206. (PMID: 15865885)
Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31. (PMID: 231022)
N Engl J Med. 2005 Mar 10;352(10 ):987-96. (PMID: 15758009)
J Neurooncol. 2004 Feb;66(3):333-9. (PMID: 15015665)
تواريخ الأحداث: Date Created: 20070627 Date Completed: 20070717 Latest Revision: 20220321
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC5722415
DOI: 10.1120/jacmp.v8i2.2423
PMID: 17592465
قاعدة البيانات: MEDLINE
الوصف
تدمد:1526-9914
DOI:10.1120/jacmp.v8i2.2423